Sapra P, Allen T M
Department of Pharmacology, University of Alberta, Edmonton AB, Canada, T6G 2H7.
Prog Lipid Res. 2003 Sep;42(5):439-62. doi: 10.1016/s0163-7827(03)00032-8.
Antibody or ligand-mediated targeting of liposomal anticancer drugs to antigens expressed selectively or over-expressed on tumor cells is increasingly being recognized as an effective strategy for increasing the therapeutic indices of anticancer drugs. This review summarizes some recent advances in the field of ligand-targeted liposomes (LTLs) for the delivery of anticancer drugs. New approaches used in the design and optimization of LTLs is discussed and the advantages and potential problems associated with their therapeutic applications are described. New technologies are widening the spectrum of ligands available for targeting and are allowing choices to be made regarding affinity, internalization and size. The time is rapidly approaching where we will see translation of anticancer drugs entrapped in LTLs to the clinic.
抗体或配体介导的脂质体抗癌药物靶向肿瘤细胞上选择性表达或过表达的抗原，正日益被视为提高抗癌药物治疗指数的有效策略。本文综述了配体靶向脂质体（LTLs）用于递送抗癌药物领域的一些最新进展。讨论了LTLs设计和优化中使用的新方法，并描述了其治疗应用的优点和潜在问题。新技术正在拓宽可用于靶向的配体范围，并允许在亲和力、内化和大小方面做出选择。将LTLs包裹的抗癌药物应用于临床的时间正在迅速临近。
